AI analytics company raises $10M

CLEW, a Netanya, Israel-based healthcare technology company, announced that it has raised $10 million in Series B funding.

The funds are expected to go toward commercializing CLEW’s AI analytics platform in the tele-ICU and critical care markets. The platform was designed to improve clinical outcomes and cut costs by helping providers predict life-threatening complications in advance.

“We view this round of funding as further validation of our technology and product offering,” CLEW CEO Gal Salomon said in a prepared statement.

Pitango Venture Capital led the funding round, with all of the company’s previous investors also contributing. Relyens, a healthcare-focused mutual group insurance and risk manager, also provided “additional strategic participation.”

“CLEW has clearly demonstrated the value that AI can bring to critical care” Ittai Harel, managing general partner at Pitango Venture Capital, said in the same statement. “We are pleased to have led this round of funding and look forward working with CLEW as they expand their footprint in the U.S.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup